Dysautonomia: Familial

Encyclopedia of Neuroscience

Volumn , Issue , 2009, Pages 737-740

  Gold Von Simson, G ^a   Axelrod, F B ^a   Slaugenhaupt, S A ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Autonomic nervous system; Central and peripheral nervous systems; Familial dysautonomia; Hereditary sensory and autonomic neuropathy; IKAP; IKBKAP; MRNA splicing; Riley Day syndrome; Tissue specific expression; Transcriptional elongation

Indexed keywords

EID: 79954618812     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-008045046-9.00668-9     Document Type: Chapter

References (14)

1. Anderson S.L., Coli R., Daly I.W., et al. Familial dysautonomia is caused by mutations of the IKAP gene. American Journal of Human Genetics 2001, 68:753-758.
2. Anderson S.L., Qiu J., Rubin B.Y. Tocotrienols induce IKBKAP expression: A possible therapy for familial dysautonomia. Biochemical and Biophysical Research Communications 2003, 306:303-309.
3. Anderson S.L., Qiu J., Rubin B.Y. EGCG corrects aberrant splicing of IKAP mRNA in cells from patients with familial dysautonomia. Biochemical and Biophysical Research Communications 2003, 310:627-633.
4. Axelrod F.B. Hereditary sensory and autonomic neuropathies: Familial dysautonomia and other HSANs. Clinical Autonomic Research 2002, 12:2-14.
5. Axelrod F.B. Autonomic and sensory disorders. Principles and Practice of Medical Genetics 2007, 2802-2816. Churchill Livingstone, Philadelphia. 5th edn. D.L. Rimoin, J.M. Connor, R.E. Pyeritz, B.R. Korf (Eds.).
6. Axelrod F.B., Goldberg J.D., Ye X.Y., Maayan C. Survival in familial dysautonomia: Impact of early intervention. Journal of Pediatrics 2002, 141:518-523.
7. Axelrod F.B., Goldstein D.S., Holmes C., Berlin D., Kopin I.J. Pattern of plasma levels of catecholamines in familial dysautonomia. Clinical Autonomic Research 1996, 6:205-209.
8. Axelrod F.B., Zupanc M., Hilz M.J., Kramer E.L. Ictal SPECT during autonomic crisis in familial dysautonomia. Neurology 2000, 55:122-125.
9. Bernardi L., Hilz M., Stemper B., Passino C., Welsch G., Axelrod F.B. Respiratory and cerebrovascular responses to hypoxia and hypercapnia in familial dysautonomia. American Journal of Respiratory and Critical Care Medicine 2002, 167:141-149.
10. Close P., Hawkes N., Cornez I., et al. Transcription impairment and cell migration defects in elongator-depleted cells: Implication for familial dysautonomia. Molecular Cell 2006, 22:521-531.
11. Hims M.M., Ibrahim E.C., Leyne M., et al. Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomia. Journal of Molecular Medicine 2007, 85:149-161.
12. Ibrahim E.C., Hims M.M., Shomron N., Burge C.B., Slaugenhaupt S.A., Reed R. Weak definition of IKBKAP exon 20 leads to aberrant splicing in familial dysautonomia. Human Mutation 2007, 28:41-53.
13. Slaugenhaupt S.A., Blumenfeld A., Gill S.P., et al. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. American Journal of Human Genetics 2001, 68:598-605.
14. Slaugenhaupt S.A., Mull J., Leyne M., et al. Rescue of a human mRNA splicing defect by the plant cytokinin kinetin. Human Molecular Genetics 2004, 13:429-436.